Replies to post #3297 on Marker Therapeutics Inc (MRKR)

[Bio7mm]

The Mayo class I antigen for HER2/neu mentioned in the letter is a real game changer since no other company has access to it. Go back to the April 16, 2012 press release to read why it is so special. Basically it is naturally occurring. That class I antigen, the class II antigens, TAP and PolyStart make an unrivaled combination that should become the gold standard for HER2/neu cancers in my opinion.